Tumor activated prodrugs
US7635682B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2006 |
| Grant date | Dec 22, 2009 |
| Priority date | — |
| Expiry date | Aug 27, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K7/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1);Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.